Presentation Transcript

1. Water Soluble HybridTaxol(Ready-to-Use)May be a new drug for cancer

   Dr. Mewa Singh 609-902-7128 mewasinghsandhu@hotmail.com www.nanosgroup.com TaxolMew Next Generation Nano READY FOR TRIALS
2. Water Soluble Taxol The Water Soluble Taxol without castor, ethanol or protein. Our Taxol is ready-to-use formulation, just add WFI before administration. Ready to use feature reduce cost. There is significant unmet medical need for more convenient and highly efficacious chemotherapy treatments with improved tolerability profiles that may allow more patients to receive optimal therapy. I believe our taxol may deliver all these benefits
3. Water Soluble Taxol Rational Taxol is a most valuable therapeutic drug Most significant disadvantage among all is low solubility owing to it , most of formulations are with castor oil ( toxic) , ethanol and albumin High toxicity (Much of the clinical toxicity of paclitaxel is associated with the solvent Cremophor EL in which it is dissolved for delivery) Some tumor cells become taxol resistant We overcome the problem and successfully eliminated the use of Castor oil, ethanol , detergent or Albumin .Hence, toxicity
4. Water Soluble Taxol Improvement There is always a room to improve a drug, But in case of Taxol, there is lot of room to improve We took opportunity of that Improved solubility and bio-availability Reduced toxicity Improved potency Also kill Taxol resistance tumor cells
5. Water Soluble Taxol Opportunity Bristol Myers Squibb Co. made $5-million a day as from taxol The introduction of improved versions of already approved treatments is a priority for health care providers to reduce cost and increase the availability of life-saving medicines Our taxol is less toxic more potent and free from side effects comes from castor oil, ethanol or albumin.
6. Water Soluble Taxol The Opportunity Taxol is an approved drug Our water soluble taxol formulation is more potent and less toxic A $5B market will be patent free and new patented advanced formulation is a real opportunity. We believe to decrease cost and increase the profit with our new Taxol
7. PROGRESS Proof of concept>>>>>>>>>>Completed R&D>>>>>>>>>>>>>>>>>>Completed Lab. Testing>>>>>>>>>>>>>Completed Animal Studies>>>>>>>>>>>Ongoing Manufacturing Process>Under development GMP product >>>>>>>>>>>>Needed Bioequivalence>>>>>>>>>>> Needed $1M Invested With time $3M Needed Exit-1st- $$20M Exit-2nd- $$100M
8. Milestone and Funds Chemistry Analytical tools GMP production Animal studies Partial Clinical trials $3M Needed
9. Last Deal Now that Celgene has wrapped up its $3 billion-plus buyout of AbraxisBioScience, analysts are cheering. That wasn't necessarily the case in June, when the companies announced their deal--and investors responded by selling off their stock, sending the price plummeting to $48. But as Investor's Business Daily reports, Celgene shares are now trading at near $60, and observers think the combo will eventually transform the company into a "biopharmaceutical giant."Read more: Abraxis deal done, Celgene eyes cancer franchise - FiercePharmahttp://www.fiercepharma.com/story/abaxis-deal-done-celgene-eyes-cancer-franchise/2010-10-25#ixzz1ibPApSSDSubscribe: http://www.fiercepharma.com/signup?sourceform=Viral-Tynt-FiercePharma-FiercePharma
10. Ongoing interest in Taxol Making Taxol Work More Effectively Susan Band Horwitz, Ph.D., Albert Einstein College of Medicine Internationally renowned for her discovery of the molecular mechanism of Taxol, NFCR scientist Susan Band Horwitz, Ph.D., at the Albert Einstein College of Medicine in the Bronx continues her quest to explore why tumor resistance to Taxol occurs and how to make the drug work better. Dr. Horwitz reasons that during chemotherapy treatment, tumor cells may activate a protective molecular pathway which renders tumors resistant to Taxol. Her team may have found one such molecule - a growth factor that promotes cell survival called Insulin growth factor 2 or IGF2. When the researchers added an inhibitor of IGF2 in Taxol-resistant ovarian cancer cell lines, the cancer cells became sensitive again to the chemotherapy agent. Moreover, the Horwitz team is the first to evaluate the significance of IGF2 protein level in patients' tumors. She discovered that patients with high levels of IFG2 in their tumors had worse outcomes and a shortened time for their cancer to reoccur compared to those with low levels of IGF2. With continued success in this promising research, the targeted therapies which inhibit the IGF2 pathway that are now in clinical trials to treat other diseases may be considered as candidates to overcome Taxol resistance in ovarian cancer patients. Recently, Dr. Horwitz was awarded the Lifetime Achievement Award by the American Association of Cancer Research. NFCR has been funding Dr. Susan Horwitz's research program for ten years and we applaud her for her continuing quest to find treatments that will overcome the resistance to Taxol, the agent that she knows so well and which has been used to treat over 1 million breast, ovarian, and lung cancer patients.
11. Infrastructure For Final Product LAETC has capability to conduct basic formulation LAETC has capability to produce pilot scale for animal trials LAETC has capability to produce material for clinical trial 1,2 and 3( GMP facility available for production) LAETC has capability to produce for sale( GMP facility available for production) Raw material secured Purchased enough material for clinical trials and some sale.
12. Commitment If I have to do on my own. This will take me 5-7 years, which I am doing and will continue till the final drug approval. If I get some funds , I will able to complete this all in 3 -4 years. Complete means, defined all the parameters for GMP production, animal trials and clinical trials.
13. TaxoMew Taxomew Injection Concentrate: Clinical pharmacology Unique chemical structure Taxomew has a soluble partner of hydrophilic and anti-cancer nature. This group leads to greater water solubility, obviating the need to use Cremophor, albumin , alcohol or detergent as a solvent Taxomew has a uniqe double edge sword molecule to attack the cancer more effectively. Cremophorfree Taxomew, which is formulated without polysorbate 80, is Cremophorfree , albumin free, alcohol free Taxomew should not have the severe hypersensitivity reactions as to Taxotereor to other drugs formulated with polysorbate 80 In vitro studies showed that Taxomew is more potent than paclitaxel Taxomew is potent for paclitaxel resistant cell line Injection Concentrate: Mechanism of Action disrupts the microtubular network in cells Hydrophilic
14. Action Attacked membrane antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions.1 Taxotere® binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the inhibition of mitosis in cells
15. Growth inhibition and appoptosis TaxoMew
16. Milestones IMPORTANT SAFETY INFORMATION WARNINGS: Injection Concentrate: Drug Interactions Important Safety Information Preclinical synergy with doxorubicin
17. Activity TaxolMew Taxol TaxolMew is five time more potent
18. Solubility Taxol TaxolMew TaxolMew ,100% soluble
19. Cytopathic TaxoMew 8th dilution Taxol 6th dilution
20. Activity TaxolSk TaxoMewSk
21. Potency Taxol-resistance TaxolMew Taxol resistance Same concentration TaxolMew 10x lower than taxol Taxolmew is 5 times more potent than Pacletaxil TaxolMew
22. From This Project 2. Have I done something today that improved the world? Yes I feel so! 4. Have I reviewed and honed my plans for the future? Yes! 7. Have I accomplished something worthwhile? Yes I have! 8. Have I helped someone less fortunate? By this drug , we will help them all!